MARKET

MDNAF

MDNAF

Medicenna Therapeutics Corp
OTCQX
1.110
-0.040
-3.48%
Closed 15:55 12/04 EST
OPEN
1.190
PREV CLOSE
1.150
HIGH
1.190
LOW
1.100
VOLUME
50.62K
TURNOVER
56.74K
52 WEEK HIGH
1.500
52 WEEK LOW
0.586
MARKET CAP
84.84M
P/E (TTM)
-9.1133
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDNAF last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at MDNAF last week (1117-1121)?
Weekly Report · 11/24 10:06
Medicenna Therapeutics Unveils Pipeline Progress and Immunotherapy Advances in New Corporate Presentation
Reuters · 11/18 17:30
Weekly Report: what happened at MDNAF last week (1110-1114)?
Weekly Report · 11/17 10:06
Medicenna Therapeutics GAAP EPS of -C$0.06
Seeking Alpha · 11/13 14:34
Medicenna Therapeutics Reports Q2 2026 Results and Announces Key Developments in Superkine Programs
TipRanks · 11/13 13:03
Medicenna Therapeutics reports Q2 operating costs of $5.5 million and ends quarter with $15.7 million in cash
Reuters · 11/13 12:00
MEDICENNA THERAPEUTICS CORP QTRLY EPS CAD-0.06
Reuters · 11/13 12:00
More
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Webull offers Medicenna Therapeutics Corp stock information, including OTCQX: MDNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDNAF stock methods without spending real money on the virtual paper trading platform.